March 28, 2025 — Hong Kong WinHealth Pharma Group (WinHealth Pharma) today announced that its Japanese subsidiary, WINHEALTH JAPAN Co., Ltd. (WinHealth Japan) has officially received the Type 1 Drug Manufacturing/Marketing Business License from the Japanese government, a pivotal step that officially grants the company Marketing Authorization Holder (MAH) status. This license marks the company’s formal entry into the production and sales of prescription medicines in Japan, laying a solid foundation for the group’s further expansion into Asia and international markets.
Since its establishment in 2019, WinHealth Japan has upheld strict quality management standards, committed to delivering safe and effective pharmaceutical products and medical solutions to the Japanese healthcare market. With the successful granting of its Type 1 Drug Manufacturing/Marketing Business License by the Japanese government, WinHealth Japan is now fully authorized to produce and market a broad range of pharmaceutical products, including new treatments. This achievement allows the company to fully launch its local operations and provide Japanese patients with more innovative and high-quality treatments. Furthermore, it represents a significant milestone in the group’s global strategic expansion, further accelerating the group’s efforts to increase its presence in international markets.
WinHealth Japan Receives Type 1 Drug Manufacturing/Marketing License from the Japanese Government
As part of the company’s business expansion, WinHealth Japan will inaugurate its new office in Otemachi, Chiyoda-ku, Tokyo, on April 1. The new office will not only provide a more efficient and comfortable working environment for the Japanese team but also offer strong support for accelerating drug development, expanding market reach, and enhancing innovation capabilities.
Exterior View of WinHealth Japan’s New Office in Otemachi, Chiyoda-ku, Tokyo
Jack Wang, Chairman of Hong Kong WinHealth Pharma Group, said: “The approval of the pharmaceutical manufacturing and sales license in Japan, along with the opening of our new office in Tokyo, represents a pivotal milestone in our global strategy. As a fully integrated biopharmaceutical company with capabilities across the entire value chain, grounded in China and focused on global expansion, we are dedicated to creating global healthcare ecosystems and delivering groundbreaking therapies and innovative healthcare solutions to patients worldwide. Japan is one of the most important markets in the global pharmaceutical industry, offering immense potential and significant opportunities. We will continue to leverage our strengths across product development, manufacturing, and commercialization to accelerate the market launch of our medicines in Japan, addressing the growing unmet needs of patients.”
WinHealth Japan will further strengthen its drug development and manufacturing capabilities, expand its market presence and sales network in Japan, and work towards establishing a global pharmaceutical supply chain system. This expansion into the Japanese market marks a significant milestone in WinHealth Pharma’s global strategy, further solidifying the group's position in the international healthcare sector. The group will continue to advance its global strategy, increasing its footprint across Asia and other international markets, while leveraging innovation to deliver sustainable value to patients worldwide and the healthcare industry.
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.